October 6, 2008 Diagnostic Imaging. Panel pans clinical trials justifying PET coverage Poor review of efficacy studies for applications monitored by PET registry disappoints proponents -------------------------------------------------------------------------------- PET imaging proponents reacted with dismay in August when a Centers for Medicare and Medicaid Services advisory panel found data for nine conditionally approved cancer indications of FDG-PET were too ambivalent to support CMS coverage. The nine-member Medicare Evidence Development and Coverage Advisory Committee (MedCAC) heard testimony from the Canadian Evidence-Based Practice Center in Edmonton, AB, and the American National Oncologic PET Registry on Aug. 20 in Woodland, MD.
![](https://storage.ning.com/topology/rest/1.0/file/get/396595535?profile=original)
See full article and related articles at DiagnosticImaging.com
This article was republished with permission from CMPMedica, LLC
You need to be a member of radRounds Radiology Network to add comments!
Join radRounds Radiology Network